Tools

Brandon Michael Wilkinson, Michael A. Duncan, Dan Y. Draytsel, Harish Babu
  1. Department of Neurosurgery, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, United States.

Correspondence Address:
Brandon Michael Wilkinson, Department of Neurosurgery, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, United States.

DOI:10.25259/SNI_847_2023

Copyright: © 2024 Surgical Neurology International This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Brandon Michael Wilkinson, Michael A. Duncan, Dan Y. Draytsel, Harish Babu. Metastatic choroid plexus papilloma presenting as a sellar mass: A case report and literature review. 19-Apr-2024;15:140

How to cite this URL: Brandon Michael Wilkinson, Michael A. Duncan, Dan Y. Draytsel, Harish Babu. Metastatic choroid plexus papilloma presenting as a sellar mass: A case report and literature review. 19-Apr-2024;15:140. Available from: https://surgicalneurologyint.com/surgicalint-articles/12860/

Date of Submission
19-Oct-2023

Date of Acceptance
03-Apr-2024

Date of Web Publication
19-Apr-2024

Abstract

Background: Choroid plexus papillomas (CPPs) are rare neoplasms arising from choroid plexus epithelium representing de novo formation in extraventricular sites is rare.

Case Description: A 57-year-old female with a history of a 4th ventricular CPP status post resection in 2004 and 2018 with subsequent gamma knife therapy in 2019 presented with increased thirst and urination. Since her initial surgery, she has experienced significant gait imbalance, diplopia, dysphagia, and right-sided hemiparesis and hemisensory loss. Magnetic resonance imaging revealed a new 1.5 × 1.8 cm suprasellar lesion. She underwent a left supraorbital craniotomy for tumor resection, with pathology revealing metastatic World Health Organization grade II CPP.

Conclusion: Extraventricular manifestation of CPP is rare. De novo or metastatic involvement of the sella has seldom been reported. Treatment should target gross total surgical resection. Adjuvant chemotherapy and radiation may be useful in higher-grade lesions.

Keywords: Choroid plexus papilloma, Metastatic, Sella, Supraorbital craniotomy

INTRODUCTION

Choroid plexus papillomas (CPPs) are rare neoplasms arising from choroid plexus epithelium and represent <1% of all intracranial tumors.[ 17 ] CPPs may occur in both adults and children with a slight male predilection (1.6:1).[ 7 ] The lateral ventricles are the most common location in children, while 4th ventricular tumors are more common in adults.[ 6 ] Symptoms vary based on location and regional mass effect; however, hydrocephalus is common due to cerebrospinal fluid (CSF) flow obstruction and/or overproduction. Signs of elevated intracranial pressure, including headache, nausea, vomiting, cranial nerve deficits, gait imbalance, and altered mental status are commonly seen.[ 12 ]

According to the World Health Organization (WHO) classification, choroid plexus tumors are classified as papillomas (grade I), atypical tumors (grade II), and carcinomas (CPC; grade III) based on the number of mitotic figures per high-power field on histologic examination. Papillomas are typically soft, friable masses with high vascularity.[ 15 ] The preferred treatment is gross total surgical resection and is typically curative in cases of papillomas.[ 14 ] Incomplete resection and increased mitotic activity are predictive of tumor recurrence.[ 5 ]

Less commonly, CPP may invade surrounding parenchyma or disseminate throughout the central nervous system (CNS). Cases of leptomeningeal spread and the formation of numerous cystic lesions in both the brain and spine have been reported.[ 6 , 12 , 13 ]

Here, we present a 57-year-old patient with prior 4th ventricular CPP with a solid distant metastasis to the sella, treated with supraorbital craniotomy for resection.

CASE PRESENTATION

A 57-year-old female with a history of a 4th ventricular CPP presented with increased thirst and urination. She initially underwent suboccipital craniotomy for tumor resection in 2004 and again in 2018 for tumor recurrence. She received subsequent Gamma Knife radiotherapy in 2019. Pathology from both resections revealed atypical CPP, WHO grade II. Since her initial surgery, she has experienced significant gait imbalance, diplopia, dysphagia, and right-sided hemiparesis and hemisensory loss. Surveillance magnetic resonance imaging (MRI) was done, showing an enhancing 1.5 × 1.8 cm suprasellar lesion, as well as a stable residual 5 × 5 mm lesion in the left posterolateral margin of the 4th ventricle [ Figure 1 ]. Preoperative visual field testing showed decreased left eye visual acuity without field cuts. She has patched the left eye since her initial surgery to improve diplopia. The endocrine evaluation revealed a prolactin level of 82.2 ng/mL attributed to the stalk effect without additional overt hormonal deficiency. Given the growth of the suprasellar lesion and the need for tissue diagnosis, she presented in April 2023 for left-sided craniotomy for tumor resection.


Figure 1:

(a) Preoperative axial T1-weighted magnetic resonance imaging (MRI) brain with contrast showing a 1.5 × 1.8 cm sellar mass. (b) Preoperative axial T1-weighted MRI brain with contrast showing a small 5 × 5 mm enhancing nodule in the left posterolateral margin of the 4th ventricle, representing residual choroid plexus papilloma.

 

The patient was treated with a left supraorbital craniotomy for tumor resection. Given her baseline functional status, we felt that an eyebrow incision provided the least invasive approach to access the tumor. A craniotomy was performed on the left side due to her existing right-sided deficits. We decided against an endoscopic transnasal transsphenoidal approach, given the patient’s obesity and associated increased risk for CSF leak. We additionally felt an endonasal approach and potential complications may exacerbate the patient’s baseline dysphagia. During resection, the firm lesion was densely adherent to the hypothalamic surface. Meticulous dissection with microinstruments allowed a tissue plane to be developed, and tumor resection continued toward the sellar floor. Preservation of functioning pituitary tissue was attempted; however, the normal-appearing pituitary gland was not visualized throughout tumor dissection and debulking. A small tumor was residual and densely adherent to the optic apparatus and was left behind to allow vision preservation. Closure was completed in standard fashion using a pericranial graft for watertight dural repair. Similarly to her prior surgeries, pathology revealed WHO II atypical CPP, suggesting metastasis. She developed panhypopituitarism treated with a regimen of desmopressin, levothyroxine, and hydrocortisone. She had a prolonged hospital course complicated by worsened dysphagia and altered mental status attributed to hypoxia secondary to atelectasis. Her respiratory status gradually improved with positive pressure ventilation through BiPAP, and her mental status returned to her preoperative baseline. Her worsened that dysphagia, however, did persist and ultimately required gastrostomy tube placement. Postoperative imaging demonstrated a small residual lesion within the sella [ Figure 2 ] without evidence of surrounding


Figure 2:

Postoperative T1-weighted magnetic resonance imaging brain with contrast showing expected post-surgical changes and decreased tumor volume, with an 8 × 6 mm area of tumor residual. areas of CNS insult or ischemia. She was discharged home in June 2023.

 

DISCUSSION

Although rare, there have been several documented cases of CPP with distant lesions throughout the neuroaxis. Metastatic lesions may present as solid-enhancing lesions, “drop metastases” in the spine, or leptomeningeal seeding.[ 1 , 3 ] Ortega-Martínez et al. reviewed 15 publications describing 16 patients with disseminated CPP.[ 13 ] All but one patient had primary lesions in the posterior fossa. Eleven patients had leptomeningeal spread, with variable involvement of supratentorial, infratentorial, and spinal sites. Five patients specifically had leptomeningeal involvement in the suprasellar region. Three patients developed solid parenchymal lesions, and three had new intraventricular lesions in the 3rd or 4th ventricle.

Numerous widespread cystic lesions have also been described. Johnson et al. reviewed a series of eight such patients.[ 6 ] Six patients had primary solitary lesions (five of which were in the 4th ventricle), two of which had multiple solid lesions. Cystic lesions were widely distributed throughout subarachnoid spaces, including the spine. Pathology in seven of the lesions was WHO grade I, with one patient having WHO II atypical CPP.

Given the reported cases of disseminated CPP, Mazur-Hart et al. proposed a new classification system describing the spectrum of disease.[ 12 ] Pathologic grades are subdivided based on the presence of solitary or multiple lesions. The WHO grade I multiple lesions are further described as disseminated disease, multifocal disease, Zuckerguss seeding of the leptomeninges, or ependymal disease.

Solid lesions involving the sellar region appear to be exceptionally rare. We identified eight publications describing eight patients with sellar CPP, including our own [ Table 1 ]. All previously reported patients had de novo formation of the WHO grade I CPP without evidence of metastatic spread from elsewhere. To the best of our knowledge, our case is the first to document metastatic spread from a distant lesion to the sella. Six of the eight patients reported were female. Ages ranged from 31 to 57. One patient received adjuvant radiotherapy postoperatively. MRI findings appear nonspecific, with variable degrees of contrast enhancement on T1-weighted images. One case demonstrated a large cystic component resembling craniopharyngioma.

While the mainstay of treatment involves gross total resection, the role of adjuvant therapies is less well-established. Chemotherapy, particularly in cases of CPC, has been reported to increase overall survival.[ 18 ] Although data regarding specific dosing regimens is largely lacking, etoposide, vincristine, cisplatin, cyclophosphamide, carboplatin, or ifosfamide are most commonly utilized. In a randomized trial, Wolff et al. noted an improved 5- and 10-year progression-free survival in patients receiving carboplatin versus cyclophosphamide in combination with etoposide and vincristine for higher-grade lesions.[19] Regimens consisted of six cycles of chemotherapy every 28 days using etoposide 100 mg/m2 on days 1–5, vincristine 1.5 mg/m2 on day 1, and either carboplatin 350 mg/m2 or cyclophosphamide 1 mg/m2 on days 1–2. Fractionated radiation therapy may also be used in select cases.


Table 1:

Summary of reported CPP cases in the sellar region.

 

The findings in our case highlight the importance of recognizing potential metastasis in CPP, including new lesions that may arise in extraventricular locations. Sellar lesions may mimic typical adenomas or craniopharyngioma; however, in patients with a history of known CPP, metastatic disease should remain in the differential. Multiple lesions may arise regardless of pathologic grade. Surveillance imaging remains essential, and full neuroaxis imaging should be considered to identify potential distant spread.

CONCLUSION

Extraventricular manifestation of CPP is rare. De novo or metastatic involvement of the sella has seldom been reported. Treatment should involve gross total surgical resection to prevent recurrence. Adjuvant chemotherapy and radiation may be appropriate in higher-grade lesions.

Ethical approval

The Institutional Review Board approval is not required.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.

References

1. Abdulkader MM, Mansour NH, Van Gompel JJ, Bosh GA, Dropcho EJ, Bonnin JM. Disseminated choroid plexus papillomas in adults: A case series and review of the literature. J Clin Neurosci. 2016. 32: 148-54

2. Bian LG, Sun QF, Wu HC, Jiang H, Sun YH, Shen JK. Primary choroid plexus papilloma in the pituitary fossa: Case report and literature review. Acta Neurochir (Wien). 2011. 153: 851-7

3. Demir MK, Özdamarlar U, Yılmaz B, Akakın A, Kılıc T. Magnetic resonance imaging of unusual neoplasms related to foramen of luschka: A review for differential diagnosis. Indian J Radiol Imaging. 2022. 32: 71-80

4. Gong X, Liu C, Zhang L, Li Z, Bartley CM, Liu Z. A primary pigmented choroid plexus papilloma located within the sella turcica: Case report and literature review. World Neurosurg. 2017. 105: 1039.e13-8

5. Jeibmann A, Hasselblatt M, Gerss J, Wrede B, Egensperger R, Beschorner R. Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropathol Exp Neurol. 2006. 65: 1069-73

6. Johnson GW, Mian AY, Dahiya S, Rich KM, Chicoine MR, Limbrick DD. Cystic dissemination of choroid plexus papilloma: Illustrative cases. J Neurosurg Case Lessons. 2022. 4: CASE22360

7. Kabashi A, Ahmetgjekaj I. Choroid plexus papilloma-case presentation. Curr Health Sci J. 2021. 47: 310-3

8. Keskin F, Erdi F, Kaya B, Toy H. Sellar-suprasellar extraventricular choroid plexus papilloma: A case report and review of the literature. J Korean Neurosurg Soc. 2016. 59: 58-61

9. Kimura M, Takayasu M, Suzuki Y, Negoro M, Nagasaka T, Nakashima N. Primary choroid plexus papilloma located in the suprasellar region: Case report. Neurosurgery. 1992. 31: 563-6

10. Kuo CH, Yen YS, Tu TH, Wu JC, Huang WC, Cheng H. Primary choroid plexus papilloma over sellar region mimicking with craniopharyngioma: A case report and literature review. Cureus. 2018. 10: e2849

11. Ma YH, Ye K, Zhan RY, Wang LJ. Primary choroid plexus papilloma of the sellar region. J Neurooncol. 2008. 88: 51-5

12. Mazur-Hart DJ, Yaghi NK, Larson EW, Pang BW, Woltjer RL, Pettersson DR. Rare case of pediatric disseminated choroid plexus papilloma: Literature review and call for reclassification. Pediatr Neurosurg. 2022. 57: 348-57

13. Ortega-Martínez M, Cabezudo-Artero JM, FernándezPortales I, Pimentel JJ, Gómez de Tejada R. Diffuse leptomeningeal seeding from benign choroid plexus papilloma. Acta Neurochir (Wien). 2007. 149: 1229-37

14. Pencalet P, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, Brunelle F, Sgouros S. Papillomas and carcinomas of the choroid plexus in children. J Neurosurg. 1998. 88: 521-8

15. Ruggeri L, Alberio N, Alessandrello R, Cinquemani G, Gambadoro C, Lipani R. Rapid malignant progression of an intraparenchymal choroid plexus papillomas. Surg Neurol Int. 2018. 9: 131

16. Sameshima T, Tanikawa R, Sugimura T, Izumi N, Seki T, Maeda T. Choroid plexus papilloma originating in the sella turcica-case report. Neurol Med Chir (Tokyo). 2010. 50: 144-6

17. Sharma R, Rout D, Gupta AK, Radhakrishnan VV. Choroid plexus papillomas. Br J Neurosurg. 1994. 8: 169-77

18. Tavallaii A, Keykhosravi E, Rezaee H, Kianbakht C. Role of available adjuvant therapies following surgical resection of atypical choroid plexus papilloma-a systematic review and pooled analysis. Neurooncol Adv. 2020. 2: vdaa139

19. Wolff JE, Van Gool SW, Kutluk T, Diez B, Kebudi R, Timmermann B. Final results of the choroid plexus tumor study CPT-SIOP-2000. J Neurooncol. 2022. 156: 599-613

Leave a Reply

Your email address will not be published. Required fields are marked *